DDInter1021 DDInter1658
Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed as _Somatuline_. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Lanreotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bromocriptine
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurasidone
Lanreotide {u} may lead to a major life threatening interaction when taken with {v} Lonafarnib
Lanreotide {u} may lead to a major life threatening interaction when taken with {v} Copper oxodotreotide Cu-64
Lanreotide may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Lanreotide may lead to a major life threatening interaction when taken with Lonafarnib
Lanreotide may lead to a major life threatening interaction when taken with Copper oxodotreotide Cu-64